While Restructuring, Acer Continues Development of Edsivo for vEDS
Acer Therapeutics announced that although it is going through a restructuring process, it stays committed to advancing the development of Edsivo (celiprolol), a potential treatment for vascular Ehlers-Danlos syndrome (vEDS). In June, the U.S. Food and Drug Administration (FDA) issued a complete response letter…